Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HBA1c and Diagnosis of Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01184768
Recruitment Status : Completed
First Posted : August 19, 2010
Last Update Posted : July 20, 2011
Sponsor:
Information provided by:
University of Tromso

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Following the 6th Tromso study subjects with HbA1c > 5.7 plus a subsample of subjects with lower hba1c values will be invited to an oral glucose tolerance test to see the predictive value of HBA1c in the diagnosis of type 2 diabetes.

Condition or disease
Type 2 Diabetes

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 3509 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: HBA1c and Diagnosis of Type 2 Diabetes
Study Start Date : January 2008
Actual Primary Completion Date : October 2010
Actual Study Completion Date : November 2010

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
participants in the 6th tromsø study


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of subjects with new diagnosis of type 2 diabetes [ Time Frame: Up to 2 years after participation in the 6th Tromso study ]

Secondary Outcome Measures :
  1. Number of subjects with new diagnosis of impaired glucose tolerance [ Time Frame: Up to 2 years after participation in the 6th Tromso study ]
  2. Number of subjects with new diagnosis of impaired fasting glucose [ Time Frame: Up to 2 years after participation in the 6th Tromso study ]
  3. Effect of vitamin D status on glucose tolerance [ Time Frame: Up to 2 years after participation in the 6th Tromso study ]

Biospecimen Retention:   Samples Without DNA
serum

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
random sample of subjects living in Tromso and who participated in the 6 th Tromsø study
Criteria

Inclusion Criteria:

  • participated in the 6 Tromso study

Exclusion Criteria:

  • type 2 diabetes
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01184768


Locations
Layout table for location information
Norway
University Hospital of North Norway
Tromsø, Norway, 9038
Sponsors and Collaborators
University of Tromso
Investigators
Layout table for investigator information
Principal Investigator: rolf jorde, md University of Tromso
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Rolf Jorde, University of Tromsø
ClinicalTrials.gov Identifier: NCT01184768    
Other Study ID Numbers: UIT-ENDO-2010-2
First Posted: August 19, 2010    Key Record Dates
Last Update Posted: July 20, 2011
Last Verified: July 2011
Keywords provided by University of Tromso:
type 2 diabetes
HbA1c
vitamin D
diagnosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases